Novartis Gets EU Approval For Skin Cancer Drugs Tafinlar, Mekinist
September 01 2015 - 2:32AM
Dow Jones News
By Neil MacLucas
ZURICH--European regulators have approved Novartis AG's (NVS)
tafinlar and mekinist for treating patients with an aggressive type
of skin cancer, the company said Tuesday.
Basel-based Novartis said the European Commission approved the
combination of tafinlar and mekinist for treating adults with
metastatic melanoma, the most serious and life-threatening form of
skin cancer and associated with low survival rates. Around 200,000
new cases of melanoma are diagnosed globally each year, according
to the International Agency for Research on Cancer .
Tafinlar and mekinist have already been granted approval in the
U.S., Australia, Canada and several other countries.
-Write to Neil MacLucas at neil.maclucas@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
September 01, 2015 02:17 ET (06:17 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
